Antonio Recchiuti

Mucus plugging and non‐resolving inflammation are inherent features of cystic fibrosis (CF) that may lead to progressive lung disease and exercise intolerance, which are the main causes of morbidity and mortality for people with CF. Therefore, understanding the influence of mucus on basic mechanisms underlying the inflammatory response and identifying strategies to resolve mucus‐driven airway inflammation and consequent morbidity in CF are of wide interest. Here, we investigated the effects of the proresolving lipid mediator resolvin (Rv) D1 on mucus‐related inflammation as a proof‐of‐concept to alleviate the burden of lung disease and restore exercise intolerance in CF. We tested the effects of RvD1 on inflammatory responses of human organotypic airways and leukocytes to CF mucus and of humanized mice expressing the epithelial Na + channel (βENaC‐Tg) having CF‐like mucus obstruction, lung disease, and physical exercise intolerance. RvD1 reduced pathogenic phenotypes of CF‐airway supernatant (ASN)‐stimulated human neutrophils, including loss of L‐selectin shedding and CD16. RNASeq analysis identified select transcripts and pathways regulated by RvD1 in ASN‐stimulated CF bronchial epithelial cells that are involved in sugar metabolism, NF‐κB activation and inflammation, and response to stress. In in vivo inflammation using βENaC TG mice, RvD1 reduced total leukocytes, PMN, and interstitial Siglec‐MΦ when given at 6–8 weeks of age, and in older mice at 10–12 weeks of age, along with the decrease of pro‐inflammatory chemokines and increase of anti‐inflammatory IL‐10. Furthermore, RvD1 treatment promoted the resolution of pulmonary exacerbation caused by Pseudomonas aeruginosa infection and significantly enhanced physical activity and energy expenditure associated with mucus obstruction, which was impaired in βENaC‐Tg mice compared with wild‐type. These results demonstrate that RvD1 can rectify features of CF and offer proof‐of‐concept for its therapeutic application in this and other muco‐obstructive lung diseases.